Value of Innovative Medicines

Many lower and middle-income countries are making important investment in developing their healthcare infrastructure as part of their commitment to achieving Universal Health Coverage. Increasing access to new medicines and vaccines can help sustain such investment by reducing the need for costly surgical interventions and hospitalization.

In many cases, the use of innovative medicines by health systems can pay for themselves several times over. One study found that a reduction in the age of drugs used reduces non-drug spending 7.2 times as much as it increases drug expediture, with most of the savings coming from reduced hospitalization and physician office-visit expenditures.

Vaccines, for instance, have proven to be one of the most effective preventative technologies in the fight against infectious diseases with an almost unparalleled impact on public health, saving the lives of over 2.5 million children each year. Estimates show that increasing access to six vaccines (including new vaccines for rotavirus and malaria) could save USD 6.2 billion in treatment costs globally . Increased productivity due to averted illness could gain the world an additional $145bn. The upfront cost of procuring vaccines is dwarfed by these benefits.

In addition to these economic benefits, the innovation we bring along has transformed the lives of millions of patients all over the world. For instance, improvements in existing cancer treatments have cut annual death rates by half in the United States. High cholesterol and other heart diseases, which required extensive treatment in the 1970s, can now be easily managed with oral therapy. Our industry has played a crucial role in researching and developing the medicines that have contributed to this.